Arrowhead says its investigational drug reduced pancreatitis events in a high-risk group, while new cholesterol data remain early and Medicare Part B billing figures in circulating reports could not be verified.
Arrowhead Pharmaceuticals has reported a striking result for patients at high risk of pancreatitis: among trial participants with triglycerides above 880 milligrams per deciliter and a history of the disease, the company said plozasiran reduced pancreatitis events by 100% compared with placebo. Arrowhead said it plans to submit a supplemental application to the Food and Drug Administration by the end of 2026.
The finding is potentially consequential for patients facing a serious complication of severe hypertriglyceridemia. But it is a company-reported result, not an FDA conclusion. Plozasiran remains investigational, and the available information does not provide the subgroup’s size, the number of events, or enough detail to assess how the result translates into a patient’s absolute risk. A relative reduction, even one reported as 100%, does not by itself establish how many people would avoid an event in routine care.
Arrowhead also reported new results for ARO-DIMER-PA, another investigational treatment. After a single dose, mean LDL-cholesterol reductions ranged from 26% to 65%, while median triglycerides fell between 56% and 78% from baseline, according to a report published by StockTitan. Those figures describe changes in laboratory measures, not evidence in the material of fewer heart attacks, pancreatitis cases or deaths. The results are early and should not be confused with proof of clinical benefit or an approved treatment option.
The company’s planned FDA submission will put the evidence, including the risks and benefits for intended patients, before regulators. Any eventual coverage and out-of-pocket cost would be separate questions. Neither the reported findings nor the submission plan establishes what the medicine would cost, whether insurers would cover it, or what conditions they might place on access.
That distinction matters in a health system where a promising therapy can be only the first step between a trial result and a patient receiving treatment. FDA review evaluates whether a drug may be marketed for a proposed use; insurance decisions determine what a covered patient may actually pay and which patients qualify under a plan. No pricing or coverage information for either Arrowhead drug was included in the available reports.
Medicare Part B costs offer a different, immediate example of how coverage details affect household budgets. A FinanceBuzz headline said people who enroll in Part B while delaying Social Security could face a $609 bill. The underlying monthly premium and other 2026 figures in the supplied material could not be verified, so that dollar amount should not be treated here as confirmed. The material does indicate that people who have Part B but are not receiving Social Security generally are billed directly rather than having premiums withheld from a Social Security payment; beneficiaries should check current official Medicare information for their own bill and payment deadlines.
The available report also does not establish a new Medicare policy change. It highlights a practical distinction: enrollment in health coverage and receipt of Social Security are separate decisions, and the method of collecting premiums can change when benefits are not being paid. Clear, current billing information matters because missed payments can affect coverage, while unverified figures can mislead people trying to plan fixed incomes.
For now, Arrowhead’s results are a reason to watch the evidence and the FDA process, not to assume a treatment is ready or affordable. The key questions ahead are whether regulators find the data adequate, whether benefits are confirmed in the patients most at risk, and what patients would pay if a drug reaches the market. On Medicare billing, the responsible answer is equally plain: confirm the amount with official sources before acting on a headline.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.